Journal for ImmunoTherapy of Cancer (JITC) is an open access, peer reviewed journal that encompasses all aspects of tumor immunology and cancer immunotherapy, from basic research through to clinical applications.
Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors
来源期刊：Journal for Immunotherapy of CancerDOI：10.1186/s40425-019-0805-8
Prognostic impact of immune gene expression signature and tumor infiltrating immune cells in localized clear cell renal cell carcinoma
来源期刊：Journal for Immunotherapy of CancerDOI：10.1186/s40425-019-0621-1
Optimized fractionated radiotherapy with anti-PD-L1 and anti-TIGIT: a promising new combination
来源期刊：Journal for Immunotherapy of CancerDOI：10.1186/s40425-019-0634-9
Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies
来源期刊：Journal for Immunotherapy of CancerDOI：10.1186/s40425-019-0724-8
Delayed immune-related events (DIRE) after discontinuation of immunotherapy: diagnostic hazard of autoimmunity at a distance
来源期刊：Journal for Immunotherapy of CancerDOI：10.1186/s40425-019-0645-6
Immunotherapy in hepatocellular carcinoma: the complex interface between inflammation, fibrosis, and the immune response
来源期刊：Journal for Immunotherapy of CancerDOI：10.1186/s40425-019-0749-z
Suppression of Myeloid Cell Arginase Activity leads to Therapeutic Response in a NSCLC Mouse Model by Activating Anti-Tumor Immunity
来源期刊：Journal for Immunotherapy of CancerDOI：10.1186/s40425-019-0504-5
Immunotherapy of triple-negative breast cancer with cathepsin D-targeting antibodies
来源期刊：Journal for Immunotherapy of CancerDOI：10.1186/s40425-019-0498-z
Phase 1/2 study of epacadostat in combination with ipilimumab in patients with unresectable or metastatic melanoma
来源期刊：Journal for Immunotherapy of CancerDOI：10.1186/s40425-019-0562-8
A phase II clinical trial of adoptive transfer of haploidentical natural killer cells for consolidation therapy of pediatric acute myeloid leukemia
来源期刊：Journal for Immunotherapy of CancerDOI：10.1186/s40425-019-0564-6
The correlations of tumor mutational burden among single-region tissue, multi-region tissues and blood in non-small cell lung cancer
来源期刊：Journal for Immunotherapy of CancerDOI：10.1186/s40425-019-0581-5
Anti-pancreatic tumor efficacy of a Listeria-based, Annexin A2-targeting immunotherapy in combination with anti-PD-1 antibodies
来源期刊：Journal for Immunotherapy of CancerDOI：10.1186/s40425-019-0601-5
Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma
来源期刊：Journal for Immunotherapy of CancerDOI：10.1186/s40425-019-0723-9
Niclosamide, an antihelmintic drug, enhances efficacy of PD-1/PD-L1 immune checkpoint blockade in non-small cell lung cancer
来源期刊：Journal for Immunotherapy of CancerDOI：10.1186/s40425-019-0733-7
Blood-derived dendritic cell vaccinations induce immune responses that correlate with clinical outcome in patients with chemo-naive castration-resistant prostate cancer
来源期刊：Journal for Immunotherapy of CancerDOI：10.1186/s40425-019-0787-6
Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system
来源期刊：Journal for Immunotherapy of CancerDOI：10.1186/s40425-019-0754-2
Response to targeted therapy or chemotherapy following immunotherapy in patients with gastrointestinal cancers - a case series
来源期刊：Journal for Immunotherapy of CancerDOI：10.1186/s40425-019-0637-6
Late-differentiated effector neoantigen-specific CD8+ T cells are enriched in peripheral blood of non-small cell lung carcinoma patients responding to atezolizumab treatment
来源期刊：Journal for Immunotherapy of CancerDOI：10.1186/s40425-019-0695-9
T cells expressing NKG2D chimeric antigen receptors efficiently eliminate glioblastoma and cancer stem cells
来源期刊：Journal for Immunotherapy of CancerDOI：10.1186/s40425-019-0642-9
Discovery of low-molecular weight anti-PD-L1 peptides for cancer immunotherapy
来源期刊：Journal for Immunotherapy of CancerDOI：10.1186/s40425-019-0705-y
Case series of cancer patients who developed cholecystitis related to immune checkpoint inhibitor treatment
来源期刊：Journal for Immunotherapy of CancerDOI：10.1186/s40425-019-0604-2
Tbet-positive regulatory T cells accumulate in oropharyngeal cancers with ongoing tumor-specific type 1\u2009T cell responses
来源期刊：Journal for Immunotherapy of CancerDOI：10.1186/s40425-019-0497-0
Chemotherapy accelerates immune-senescence and functional impairments of Vδ2pos T cells in elderly patients affected by liver metastatic colorectal cancer
来源期刊：Journal for Immunotherapy of CancerDOI：10.1186/s40425-019-0825-4
Inflammatory signatures for quick diagnosis of life-threatening infection during the CAR T-cell therapy
来源期刊：Journal for Immunotherapy of CancerDOI：10.1186/s40425-019-0767-x
Epigenetic alterations are associated with tumor mutation burden in non-small cell lung cancer
来源期刊：Journal for Immunotherapy of CancerDOI：10.1186/s40425-019-0660-7
Characterization of a whole blood assay for quantifying myeloid-derived suppressor cells
来源期刊：Journal for Immunotherapy of CancerDOI：10.1186/s40425-019-0674-1
Multiple antigen-engineered DC vaccines with or without IFNα to promote antitumor immunity in melanoma
来源期刊：Journal for Immunotherapy of CancerDOI：10.1186/s40425-019-0552-x
Antitumor response to microscopic melanoma in the gastric mucosa mimicking ipilimumab-induced gastritis
来源期刊：Journal for Immunotherapy of CancerDOI：10.1186/s40425-019-0524-1
Remembering the forgotten child: the role of immune checkpoint inhibition in patients with human immunod eficiency virus and cancer
来源期刊：Journal for Immunotherapy of CancerDOI：10.1186/s40425-019-0618-9
Unchecked immunity: a unique case of sequential immune-related adverse events with Pembrolizumab
来源期刊：Journal for Immunotherapy of CancerDOI：10.1186/s40425-019-0727-5
Temporal changes within the (bladder) tumor microenvironment that accompany the therapeutic effects of the immunocytokine NHS-IL12
来源期刊：Journal for Immunotherapy of CancerDOI：10.1186/s40425-019-0620-2
Immunoglobulin somatic hypermutation has clinical impact in DLBCL and potential implications for immune checkpoint blockade and neoantigen-based immunotherapies
来源期刊：Journal for Immunotherapy of CancerDOI：10.1186/s40425-019-0730-x
Recovery from secondary adrenal insufficiency in a patient with immune checkpoint inhibitor therapy induced hypophysitis
来源期刊：Journal for Immunotherapy of CancerDOI：10.1186/s40425-019-0729-3
Hypothesis: does adrenalitis caused by immune checkpoint-inhibitors put melanoma patients at an elevated risk for recurrence?
来源期刊：Journal for Immunotherapy of CancerDOI：10.1186/s40425-019-0651-8
Correction to: Vaccination with nanoparticles combined with micro-adjuvants protects against cancer
来源期刊：Journal for Immunotherapy of CancerDOI：10.1186/s40425-019-0616-y
TLR9 acts as a sensor for tumor-released DNA to modulate anti-tumor immunity after chemotherapy
来源期刊：Journal for Immunotherapy of CancerDOI：10.1186/s40425-019-0738-2
Plasmacytoid dendritic cells orchestrate innate and adaptive anti-tumor immunity induced by oncolytic coxsackievirus A21
来源期刊：Journal for Immunotherapy of CancerDOI：10.1186/s40425-019-0632-y
Metastatic Merkel cell carcinoma and myasthenia gravis: contraindication for therapy with immune checkpoint inhibitors?
来源期刊：Journal for Immunotherapy of CancerDOI：10.1186/s40425-019-0626-9
Immune induction strategies to enhance responses to PD-1 blockade: lessons from the TONIC trial
来源期刊：Journal for Immunotherapy of CancerDOI：10.1186/s40425-019-0783-x
Interleukin-15 in cancer immunotherapy: IL-15 receptor complex versus soluble IL-15 in a cancer cell-delivered murine leukemia model
来源期刊：Journal for Immunotherapy of CancerDOI：10.1186/s40425-019-0777-8
Carboplatin/paclitaxel, E7-vaccination and intravaginal CpG as tri-therapy towards efficient regression of genital HPV16 tumors
来源期刊：Journal for Immunotherapy of CancerDOI：10.1186/s40425-019-0593-1
Pericardial effusion under nivolumab: case-reports and review of the literature
来源期刊：Journal of Immunotherapy for CancerDOI：10.1186/s40425-019-0760-4
Development of a prognostic composite cytokine signature based on the correlation with nivolumab clearance: translational PK/PD analysis in patients with renal cell carcinoma
来源期刊：Journal for Immunotherapy of CancerDOI：10.1186/s40425-019-0819-2
Correction to: persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1
来源期刊：Journal for Immunotherapy of CancerDOI：10.1186/s40425-019-0547-7
Molecular and metabolic pathways mediating curative treatment of a non-Hodgkin B cell lymphoma by Sindbis viral vectors and anti-4-1BB monoclonal antibody
来源期刊：Journal for Immunotherapy of CancerDOI：10.1186/s40425-019-0664-3
Correction to: Immunotherapy Utilizing the Combination of Natural Killer– and Antibody Dependent Cellular Cytotoxicity (ADCC)–Mediating Agents with Poly (ADP-ribose) polymerase (PARP) Inhibition
来源期刊：Journal for Immunotherapy of CancerDOI：10.1186/s40425-019-0715-9
Correction to: Pericardial effusion under nivolumab: case-reports and review of the literature
来源期刊：Journal for Immunotherapy of CancerDOI：10.1186/s40425-019-0822-7
Correction to: Prognostic impact of immune gene expression signature and tumor infiltrating immune cells in localized clear cell renal cell carcinoma
来源期刊：Journal for Immunotherapy of CancerDOI：10.1186/s40425-019-0735-5
34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019): part 1
来源期刊：Journal for Immunotherapy of CancerDOI：10.1186/s40425-019-0763-1
Peritumoral administration of DRibbles-pulsed antigen-presenting cells enhances the antitumor efficacy of anti-GITR and anti-PD-1 antibodies via an antigen presenting independent mechanism
来源期刊：Journal for Immunotherapy of CancerDOI：10.1186/s40425-019-0786-7
